Mglirijeng 10 mg (Empagliflozin)

Adult dose

The recommended dosage of this medication for both monotherapy and additional combination therapy with insulin or other blood sugar-lowering agents is 10 mg once daily. If additional blood sugar control is needed and tolerance is good, the dosage can be increased to 25 mg once daily. It can be administered regardless of meals, and the tablet should be swallowed whole. If a dose is missed, take it as soon as remembered, but do not take double the dosage in one day.

This medication should not be used in certain patients. First, it should not be administered to patients allergic to the active ingredient or components of this medication. Second, it is not suitable for patients with type 1 diabetes or diabetic ketoacidosis. Third, it should not be given to patients with severely impaired kidney function, end-stage renal disease, or those on dialysis. Fourth, it should not be used in patients with genetic lactose intolerance, galactose intolerance, or lactose enzyme deficiency. For patients with some degree of impaired kidney function, this medication should be administered with caution. Especially in patients with a glomerular filtration rate of less than 60 ml/min/1.73m2, it is advisable not to use this medication from the start. Even if the tolerance to this medication is good, the dose should be adjusted or maintained. If the glomerular filtration rate continues to drop below 45 ml/min/1.73m2, this medication should be discontinued. This medication is not expected to be effective in patients with end-stage renal disease or those on dialysis. For patients with heart failure, especially those with mild to moderate (NYHA class I-II) symptoms, caution should be exercised. It is not recommended for severe (NYHA class III-IV) patients due to a lack of clinical trial experience. The risk of hypoglycemia may increase when this medication is used with insulin or sulfonylureas, so the doses of these medications may need to be reduced. Possible adverse reactions that may occur with this medication include hypoglycemia, genital infections (vulvovaginitis, vulvar infections, balanitis, etc.), urinary tract infections, increased urination, skin rash, urticaria, angioedema, decreased fluid volume, increased serum creatinine, etc. Hypoglycemia, in particular, may occur more frequently when used in combination with insulin or sulfonylureas. This medication can potentially cause serious ketoacidosis, so if symptoms such as nausea, vomiting, abdominal pain, fatigue, or shortness of breath appear, you should immediately notify a doctor and undergo a ketone test regardless of blood sugar levels. Elderly patients, especially those over 75 years of age, are at a higher risk of fluid loss, so caution is needed. In situations where fluid loss is a concern, it is advisable to temporarily discontinue this medication. This medication can cause serious infections such as urinary sepsis, pyelonephritis, and necrotizing fasciitis, so if pain or discomfort occurs in the genital or perineal area, consult medical personnel immediately. Additionally, this medication requires caution due to the risk of hypoglycemia when driving or operating machinery. Women who are pregnant or planning to become pregnant are advised not to use this medication, and nursing mothers should discontinue breastfeeding while taking this medication. The safety and efficacy of this medication in children under 18 years of age have not been established. No specific toxicity symptoms have been reported in case of overdose; however, if an overdose is suspected, appropriate treatment should be sought immediately at a medical institution. This medication should be stored out of reach of children, and care should be taken as transferring it to another container may be detrimental to quality.

Serious side effects

• Urticaria
• severe swelling (angioedema)
• ketoacidosis
• urinary sepsis
• pyelonephritis
• necrotizing fasciitis
• acute kidney injury
• angioedema
• necrotizing fasciitis
• ketoacidosis

Mild side effects

• Hypoglycemia
• vulvovaginitis
• vulvar infections
• balanitis and other genital infections
• pruritus
• rash
• increased urination
• decreased fluid volume
• increased serum creatinine
• decreased glomerular filtration rate

This medication should be stored in a tightly closed container to prevent air or moisture from entering. It is best to maintain a storage temperature between 1 degree and 30 degrees Celsius.

Appearance

Pale yellow, biconvex, round film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP x 3], 30 tablets/bottle